{
    "version": "2.1.0",
    "lastUpdated": "2026-01-08",
    "evidenceSource": "CDC 2022, NCCN 2025, FDA Labels",
    "globalWarnings": [
        "MME calculations are for RISK STRATIFICATION ONLY",
        "Do NOT use calculated MME to determine doses when converting opioids",
        "When rotating opioids, reduce calculated dose by 25-50% for incomplete cross-tolerance",
        "Individual variability in genetics and pharmacokinetics cannot be accounted for",
        "Close monitoring and frequent dose titration required during opioid rotation"
    ],
    "evidenceQualityDefinitions": {
        "high": "Multiple high-quality RCTs or systematic reviews with consistent results. Guideline consensus (CDC, NCCN). Direct clinical validation.",
        "moderate": "Single high-quality study, expert consensus, or pharmacokinetic modeling with clinical validation. Some variability in published ratios.",
        "low": "Pharmacokinetic extrapolation, theoretical derivation, or wide variability in published ratios. Limited clinical validation.",
        "insufficient": "No validated conversion factor available. Specialist consultation required."
    },
    "conversionFactors": {
        "fentanyl": {
            "routes": [
                {
                    "route": "iv_acute",
                    "factor": 0.3,
                    "unit": "mcg/day",
                    "evidenceQuality": "high",
                    "source": "FDA Label + NCCN 2025",
                    "citation": "100 mcg IV fentanyl = 10 mg IV morphine (single-dose)",
                    "clinicalContext": "For bolus dosing, PRN administration, or short-duration infusions."
                },
                {
                    "route": "iv_continuous",
                    "factor": 0.12,
                    "unit": "mcg/day",
                    "evidenceQuality": "moderate",
                    "source": "NCCN 2025",
                    "citation": "Steady-state ratio 250 mcg IV fentanyl = 10 mg IV morphine",
                    "clinicalContext": "For continuous infusions >24 hours. Accounts for accumulation and context-sensitive half-life.",
                    "temporalThreshold": "24 hours",
                    "pharmacokineticRationale": "Fentanyl accumulates in skeletal muscle and fat (Vd 6 L/kg). Terminal t½ 219 minutes. Steady-state reached after ~5 half-lives (18 hours)."
                },
                {
                    "route": "transdermal",
                    "factor": 2.0,
                    "unit": "mcg/hr",
                    "evidenceQuality": "high",
                    "source": "NCCN 2025 / FDA",
                    "citation": "Fentanyl transdermal conversion factor",
                    "clinicalContext": "For transdermal patches only. Onset 12-24 hours. Heat increases absorption 30%+. CONTRAINDICATED in opioid-naive patients (Black Box Warning).",
                    "warnings": [
                        "Depot effect: takes 12-24 hours to reach steady state",
                        "Heat sensitivity: fever, heating pads increase absorption",
                        "Fatal respiratory depression in opioid-naive patients",
                        "Do not use for acute pain"
                    ]
                }
            ]
        },
        "hydromorphone": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 15.0,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "NCCN 2025 / Reddy 2017",
                    "citation": "Conservative estimate. NCCN (20), Reddy (11.5). Range 10-20.",
                    "clinicalContext": "Conservative middle-ground estimate to avoid overestimation."
                },
                {
                    "route": "po",
                    "factor": 4.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Standard 1:4 ratio (7.5mg HM = 30 MME)",
                    "clinicalContext": "Standard oral conversion."
                }
            ]
        },
        "morphine": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 3.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022 / Mercadante 2010",
                    "citation": "Chronic dosing ratio 1:3 (IV:PO)",
                    "clinicalContext": "Standard chronic ratio. Acute ratio may be higher (1:6)."
                },
                {
                    "route": "po",
                    "factor": 1.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Reference Standard (1 mg = 1 MME)",
                    "clinicalContext": "Reference Standard."
                }
            ]
        },
        "methadone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 4.7,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "CDC 2022",
                    "citation": "CDC conversion factor for MME calculation only. NOT for dose conversion.",
                    "clinicalContext": "FOR RISK STRATIFICATION ONLY. Methadone conversion is non-linear and dose-dependent (ratios 2:1 to 20:1). When converting TO methadone, use tiered ratios.",
                    "warnings": [
                        "NON-LINEAR: Conversion ratio changes with dose",
                        "DO NOT use this factor to convert FROM methadone to other opioids",
                        "Risk Stratification ONLY"
                    ]
                }
            ]
        },
        "oxycodone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 1.5,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Standard 1.5:1 ratio",
                    "clinicalContext": "Consistent across guidelines."
                }
            ]
        },
        "oxymorphone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 3.0,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "FDA Label",
                    "citation": "Approximately 3x potency of oral morphine",
                    "clinicalContext": "Potent mu-agonist. 10mg Oral Oxymorphone ≈ 30mg Oral Morphine."
                },
                {
                    "route": "iv",
                    "factor": 30.0,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "Clinical Estimate",
                    "citation": "Estimated 10:1 IV:PO ratio (1mg IV ≈ 10mg PO ≈ 30mg Morphine)",
                    "clinicalContext": "Use extreme caution. IV formulation rarely used."
                }
            ]
        },
        "tramadol": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.2,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "CDC 2022",
                    "citation": "100mg Tramadol ≈ 20 MME",
                    "warnings": [
                        "Seizure risk >400mg/day",
                        "Serotonin Syndrome risk"
                    ],
                    "clinicalContext": "Dual mechanism (Mu-opioid + SNRI). Factor 0.1-0.2 used variably; CDC 2022 uses 0.2."
                }
            ]
        },
        "codeine": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.15,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "CDC 2022",
                    "citation": "200mg Codeine ≈ 30 MME",
                    "clinicalContext": "Prodrug requiring CYP2D6 metabolism. Genetic variability affects efficacy."
                }
            ]
        },
        "tapentadol": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.4,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "Manufacturer / CDC",
                    "citation": "100mg Tapentadol ≈ 40 MME",
                    "clinicalContext": "Dual mechanism (Mu-opioid + NRI). Lower GI side effect profile."
                }
            ]
        },
        "hydrocodone": {
            "routes": [
                {
                    "route": "po",
                    "factor": 1.0,
                    "unit": "mg/day",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "1:1 conversion with Morphine",
                    "clinicalContext": "Standard 1:1 ratio."
                }
            ]
        },
        "levorphanol": {
            "routes": [
                {
                    "route": "po",
                    "factor": 12.0,
                    "unit": "mg/day",
                    "evidenceQuality": "moderate",
                    "source": "FDA Label / CDC",
                    "citation": "12-15x potency of morphine. CDC uses 12.",
                    "warnings": [
                        "Long half-life (11-16h)",
                        "Accumulation risk similar to methadone"
                    ],
                    "clinicalContext": "Potent NMDA antagonist properties. Used for refractory pain."
                }
            ]
        },
        "meperidine": {
            "routes": [
                {
                    "route": "po",
                    "factor": 0.1,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "Legacy / Equianalgesic Tables",
                    "citation": "300mg Meperidine ≈ 30mg Morphine",
                    "warnings": [
                        "Neurotoxic metabolite (Normeperidine)",
                        "Seizure risk",
                        "Serotonin Syndrome",
                        "Avoid in elderly/renal failure"
                    ],
                    "clinicalContext": "NOT RECOMMENDED for chronic pain. Poor oral bioavailability."
                },
                {
                    "route": "iv",
                    "factor": 0.4,
                    "unit": "mg/day",
                    "evidenceQuality": "low",
                    "source": "Legacy",
                    "citation": "75mg IV Meperidine ≈ 30mg Morphine",
                    "clinicalContext": "Short duration. Neurotoxic risk remains."
                }
            ]
        },
        "buprenorphine": {
            "routes": [
                {
                    "route": "transdermal",
                    "factor": 0.0,
                    "unit": "mcg/hr",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Excluded from MME calculations",
                    "warnings": [
                        "Partial Agonist - MME not applicable",
                        "Do not convert linearly",
                        "QT Prolongation risk with doses > 20mcg/hr (FDA)"
                    ],
                    "clinicalContext": "Ceiling effect on respiratory depression. MME calculation is not clinically valid."
                },
                {
                    "route": "sl",
                    "factor": 0.0,
                    "unit": "mg",
                    "evidenceQuality": "high",
                    "source": "CDC 2022",
                    "citation": "Excluded from MME calculations",
                    "warnings": [
                        "Partial Agonist - MME not applicable"
                    ],
                    "clinicalContext": "Sublingual bioavailability widely variable."
                }
            ]
        },
        "sufentanil": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 1000.0,
                    "unit": "mcg",
                    "evidenceQuality": "low",
                    "source": "Anesthesia Textbooks",
                    "citation": "500-1000x potency of morphine",
                    "warnings": [
                        "Potent Anesthetic",
                        "ICU/OR Setting Only"
                    ],
                    "clinicalContext": "Extreme potency. Not for general ward use."
                }
            ]
        },
        "alfentanil": {
            "routes": [
                {
                    "route": "iv",
                    "factor": 10.0,
                    "unit": "mcg",
                    "evidenceQuality": "low",
                    "source": "Anesthesia Textbooks",
                    "citation": "10-20x potency of morphine",
                    "warnings": [
                        "Short duration",
                        "ICU/OR Setting Only"
                    ],
                    "clinicalContext": "Rapid onset/offset."
                }
            ]
        }
    }
}